Induction of potent antitumor immunity by in situ targeting of intratumoral DCs
J. Clin. Invest. Katsuyoshi Furumoto, et al. 113:774 doi:10.1172/JCI19762 [
Go to this article.]
Figure 8Intratumoral CCL20 alone or in combination with CpG induces the regression of preexisting parental tumors. (A and B) Mice were inoculated subcutaneously with 2 × 10
6 CT26 parental (A) or 5 × 10
4 B16 parental tumor cells (B). Five days later the mice were injected in the opposite flank with CT26 mock or CT26-CCL20–transduced tumor cells (A) or B16 mock or B16-CCL20–transduced tumor cells in addition to two intratumoral CpG or ODN-CTR injections (B). Graphs show the growth of distant parental tumors. Results shown are representative of two separate experiments. (A)
P < 0.05 between CCL20 and mock groups; (B)
P < 0.05 between CCL20 + CpG and the other groups. (C and D) Mice were inoculated with 2 × 10
6 CT26 parental tumors, and 0.1 μg of recombinant CCL20 protein or PBS was injected daily for 3 weeks into the tumors beginning 1 day after tumor inoculation. Results shown are from three separate experiments. *Statistical difference in tumor growth between mice treated with CCL20 compared with untreated mice (
P < 0.05). (E and F) Mice were inoculated with 5 × 10
4 B16 parental tumors, and recombinant CCL20 protein was injected into the tumors alone or in addition to five intratumoral injections of CpG as described in Methods.
